Checking in with the co-founders of Amylyx Pharmaceuticals, which now has one program in pivotal, another that may start soon, and earlier stage clinical programs that will have data this year

Josh Cohen and Justin Klee walk us through the lead program, avexitide, which is a GLP-1 antagonist and is currently in a pivotal study that will read out in 1H26. Plus, updates on AMX0035 in Wolfram Syndrome and Progressive Supranuclear Palsy, and an ALS program targeting calpain-2 that will have initial data later this year.